Cargando…

ILC2s: New Actors in Tumor Immunity

Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological proces...

Descripción completa

Detalles Bibliográficos
Autores principales: Ercolano, Giuseppe, Falquet, Maryline, Vanoni, Giulia, Trabanelli, Sara, Jandus, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902088/
https://www.ncbi.nlm.nih.gov/pubmed/31849977
http://dx.doi.org/10.3389/fimmu.2019.02801
_version_ 1783477622431285248
author Ercolano, Giuseppe
Falquet, Maryline
Vanoni, Giulia
Trabanelli, Sara
Jandus, Camilla
author_facet Ercolano, Giuseppe
Falquet, Maryline
Vanoni, Giulia
Trabanelli, Sara
Jandus, Camilla
author_sort Ercolano, Giuseppe
collection PubMed
description Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.
format Online
Article
Text
id pubmed-6902088
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69020882019-12-17 ILC2s: New Actors in Tumor Immunity Ercolano, Giuseppe Falquet, Maryline Vanoni, Giulia Trabanelli, Sara Jandus, Camilla Front Immunol Immunology Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies. Frontiers Media S.A. 2019-12-03 /pmc/articles/PMC6902088/ /pubmed/31849977 http://dx.doi.org/10.3389/fimmu.2019.02801 Text en Copyright © 2019 Ercolano, Falquet, Vanoni, Trabanelli and Jandus. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ercolano, Giuseppe
Falquet, Maryline
Vanoni, Giulia
Trabanelli, Sara
Jandus, Camilla
ILC2s: New Actors in Tumor Immunity
title ILC2s: New Actors in Tumor Immunity
title_full ILC2s: New Actors in Tumor Immunity
title_fullStr ILC2s: New Actors in Tumor Immunity
title_full_unstemmed ILC2s: New Actors in Tumor Immunity
title_short ILC2s: New Actors in Tumor Immunity
title_sort ilc2s: new actors in tumor immunity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902088/
https://www.ncbi.nlm.nih.gov/pubmed/31849977
http://dx.doi.org/10.3389/fimmu.2019.02801
work_keys_str_mv AT ercolanogiuseppe ilc2snewactorsintumorimmunity
AT falquetmaryline ilc2snewactorsintumorimmunity
AT vanonigiulia ilc2snewactorsintumorimmunity
AT trabanellisara ilc2snewactorsintumorimmunity
AT janduscamilla ilc2snewactorsintumorimmunity